Toxicological Evaluation of Disulfiram, Copper Gluconate and Disulfiram/Copper Gluconate Combination on Renal Function in Rodents
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53913#.VNsLcyzQrzE
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53913#.VNsLcyzQrzE
ABSTRACT
This
research work investigated and compared the chronic renal toxicological
profile of disulfiram, copper gluconate and disulfiram/copper gluconate
combination, in a 90-day time- and dose-dependent study in rodents. 88
rats weighing an average of 280 g divided into eleven groups consisting
of 8 rats each were used for this experiment. The control groups
received normal saline as placebo and 99.5% dimethyl sulfoxide (DMSO)
(solvent control). Three oral doses (low, medium and high) of disulfiram
(18.65 mg/kg, 37.3 mg/kg and 74.6 mg/kg), copper gluconate (3.75 mg/kg,
7.5 mg/kg and 15 mg/kg) and both drugs in combination were administered
daily with those of the combination given 12 hours apart. Blood samples
were collected via cardiac puncture in heparinised bottles and
centrifuged, and the serum was decanted on 30, 45, 60 and 90 days for
analysis. Renal function parameters—electrolytes (Na+, K+),
urea and creatinine were evaluated. Results showed significant (p <
0.05) dose- and time-dependent increase in electrolyte level (Na+, K+),
blood urea and creatinine respectively. The results are all pointers to
the development of renal failure. It therefore appears that the DSF/CG
combination is nephrotoxic and this effect is dose-dependent and
synergistic.
Cite this paper
References
Georgewill,
U. , Siminialayi, I. and Obianime, A. (2015) Toxicological Evaluation
of Disulfiram, Copper Gluconate and Disulfiram/Copper Gluconate
Combination on Renal Function in Rodents. Pharmacology & Pharmacy, 6, 86-93. doi: 10.4236/pp.2015.62011.
| [1] | World Health Organization (2008) World Cancer Report 2008. International Agency for Research on Cancer, Lyon. |
| [2] | Chukwuma, M. (2006) Crude Oil Pollution Raises Cancer Risk among Nigerians. African Cancer Centre. |
| [3] | Duran-Frigola,
M. and Aloy, P. (2012) Recycling Side Effects into Clinical Markers for
Drug Repositioning. Genome Medicine, 4, 3. http://dx.doi.org/10.1186/gm302 |
| [4] | Li, Y.Y. and Jones, S.J. (2012). Drug Repositioning for Personalised Medicine. Genome Medicine, 4, 27. |
| [5] | Blatt,
J. and Corey, S.J. (2013) Drug Repositioning in Paediatrics and
Pediatric Hematology Oncology. Drug Discovery Today, 18, 4-10. http://dx.doi.org/10.1016/j.drudis.2012.07.009 |
| [6] | Cvek,
B. (2011) Targeting Malignancies with Disulfiram(antabuse); Multidrug
Resistance, Angiogenesis, and Proteasome. Current Cancer Drug Targets,
11, 332-337. http://dx.doi.org/10.2174/156800911794519806 |
| [7] | Kast, R.E., Boockvar, J.A., Bruning, A., Capello, F., Chang, W.W., Cvek, B., Dou, Q.P., Duenas-Gonzalez, A., Efferth, T., Focosi, D., Ghaffari, S.H., Karpel-Massler, G., Ketola, K., Khoshnevisan, A., Keizman, D., Magne, N., Marosi, C., McDonald, K., Munoz, M., Paranjpe, A., Pourgholami, M.H., Sardi, I., Sella, A., Srivenugopal, K.S., Tucorri, M., Wang, W., Wirtz, C..R. and Halatsch, M.E. (2013) A Conceptually New Treatment Approach for Relapsed Glioblastoma; Coordinated Undermining of Survival Paths with Nine Repurposed Drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 4, 502-530. |
| [8] | Brar, S.S., Grigg, C., Wilson, K.S., Holder, W.D., Dreau, D., Austin, C., et al. (2010) Disulfiram Inhibits Activating Transcription Factor/Cyclic AMP Responsive Element Binding Protein and Human Melanoma Growth in a Metal-Dependent Manner in Vitro, in Mice and in a Patient with Cancer Cell Lines. Cancer Letters, 290, 104-113. |
| [9] | Marikovsky,
M., Nevo, N., Vadai, E. and Harris-Cerruti, C. (2002) Cu/Zn Superoxide
Dismutase Plays a Role in Angiogenesis. International Journal of Cancer,
97, 34-41. http://dx.doi.org/10.1002/ijc.1565 |
| [10] | Cen, D., Gonzalez, R.I., Buckmeier, J.A., Kahlon, R.S., Tohidian, N.B. and Meyskens Jr, F.L. (2002) Disulfiram Induces Apoptosis in Human Melanoma Cells: A Redox-Related Process. Molecular Cancer Therapeutics, 1, 197-204. |
| [11] | Chen,
D., Cui, Q.C., Yang, H.J. and Dou, Q.P. (2006) Disulfiram, a Clinically
Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic
Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of
the Proteasome Activity. Cancer Research, 66, 10425-10433. http://dx.doi.org/10.1158/0008-5472.CAN-06-2126 |
| [12] | Johansson,
B. (1992) A Review of the Pharmacokinetics and Pharmacodynamics of
Disulfiram and Its Metabolites. Acta Psychiatrica Scandinavica, 86,
15-26. http://dx.doi.org/10.1111/j.1600-0447.1992.tb03310.x |
| [13] | Kristenson, H. (1995) How to Get the Best out of Antabuse. Alcohol and Alcoholism, 30, 775-783. |
| [14] | Skrott,
Z. and Cvek, B. (2012) Diethyldithiocarbamate Complex with Copper: The
Mechanism of Action in Cancer Cells. Mini-Reviews in Medicinal
Chemistry, 12, 1184-1192. http://dx.doi.org/10.2174/138955712802762068 |
| [15] | Papaioannou, M., Malonas, I., Kast, R.E. and Brüning, A. (2013) Disulfiram/Copper Causes Redox-Related Proteotoxicity and Concomitant Heat Shock Response in Ovarian Cancer Cells That Is Augmented by Auranofin-Mediated Thioredoxin Inhibition. Oncoscience, 1, 21-29. |
| [16] | Ries,
F. and Klastersky, J. (1986) Nephrotoxicity Induced by Cancer
Chemotherapy with Special Emphasis on Cisplatin Toxicity. American
Journal of Kidney Diseases, 8, 368-379. http://dx.doi.org/10.1016/S0272-6386(86)80112-3 |
| [17] | Barbier,
O., Jacquillet, G., Tauc, M., Cougnon, M. and Poujeol, P. (2005) Effect
of Heavy Metals on, and Handling by, the Kidney. Nephron Physiology,
99, 105-110. http://dx.doi.org/10.1159/000083981 |
| [18] | Owunari,
G.U., Minakiri, S.I. and Wolfe, O.A. (2015) Effect of Disulfiram/Copper
Gluconate Combination on Haematological Indices in Rodents.
Pharmacology & Pharmacy, 6, 17-24. http://dx.doi.org/10.4236/pp.2015.61003 |
| [19] | Grossmann,
K.F., Blankenship, M.B., Akerley, W., Terrazas, M.C., Kosak, K.M.,
Boucher, K.M., Buys, S.S., Jones, K., Werner, T.L., Agarwal, N., Weis,
J., Sharma, S., Ward, J. and Shami, P.J. (2011) Abstract 1308: A Phase I
Clinical Study Investigating Disulfiram and Copper Gluconate in
Patients with Advanced Treatment-Refractory Solid Tumors Involving the
Liver. Cancer Research, 71, 1308. http://dx.doi.org/10.1158/1538-7445.AM2011-1308 |
| [20] | Olurishe, T.O., Kwanashie, H.O., Anukar, J.A., Muktar, H. and Sambo, J.S. (2013) Renal Impact of Subacute Lamivudine-Artesunate Treatment in Wistar Rats. African Journal of Pharmacology and Therapeutics, 2, 48-53. |
| [21] | Eaton, D.C. and Pooler, J.P. (2009) Vander’s Renal Physiology. 7th Edition, Lange Medical Books/McGraw-Hill, Medical Pub. Division, New York. |
| [22] | Traynor,
J., Mactier, R., Geddes, C.C. and Fox, J.G. (2006) How to Measure Renal
Function in Clinical Practice. British Medical Journal, 333, 733-737. http://dx.doi.org/10.1136/bmj.38975.390370.7C |
| [23] | Allen,
P.J. (2012) Creatine Metabolism and Psychiatric Disorders: Does
Creatine Supplementation Have Therapeutic Value? Neuroscience &
Biobehavioral Reviews, 36, 1442-1462. http://dx.doi.org/10.1016/j.neubiorev.2012.03.005 |
| [24] | Gross,
J.L., de Azevedo, M.J., Silveiro, S.P., Canani, L.H., Caramori, M.L.
and Zelmanovitz, T. (2005) Diabetic Nephropathy: Diagnosis, Prevention,
and Treatment. Diabetes Care, 28, 164-176. http://dx.doi.org/10.2337/diacare.28.1.164 eww150211lx |
评论
发表评论